Scholarlink

<p>We investigated the association of cystatin C with incident chronic kidney disease (CKD), defined as an estimated glomerular filtration rate (eGFR) &lt; 60 mL/min/1.73 m<sup>2</sup>. We enrolled patients with an eGFR ≥ 60 mL/min/1.73 m<sup>2</sup> who underwent an oral glucose tolerance test (OGTT) between 2011 and 2013. Patients with diabetes were excluded from the analysis. We measured their cystatin C levels, and all patients’ renal function and survival status were followed until March 2023. Cox-proportional hazard models were conducted to examine the association of cystatin C with incident CKD and all-cause mortality. A total of 146 patients were analyzed. After a median follow-up period of 10.7 years, patients with a higher cystatin C (≥ median vs. &lt; median) were independently associated with a higher risk of incident CKD and all-cause mortality (adjusted hazard ratio [HR] 2.96, 95% CI 1.09 to 8.09, <i>p</i> = 0.034). The findings were consistent when cystatin C was analyzed as a continuous variable. The association was mainly observed in patients with prediabetes (adjusted HR 5.75, 95% CI 1.34 to 24.69, <i>p</i> = 0.019). In summary, a higher cystatin C was independently associated with risk of incident CKD and all-cause mortality in non-diabetes patients with an eGFR ≥ 60 mL/min/1.73 m<sup>2</sup>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Associations of cystatin C with incident chronic kidney disease and all-cause mortality in patients with normal glucose tolerance and prediabetes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月2日

查看全文
  • Guan-Hong Lin,
  • Ching-Heng Lin,
  • Jun-Sing Wang

摘要

We investigated the association of cystatin C with incident chronic kidney disease (CKD), defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2. We enrolled patients with an eGFR ≥ 60 mL/min/1.73 m2 who underwent an oral glucose tolerance test (OGTT) between 2011 and 2013. Patients with diabetes were excluded from the analysis. We measured their cystatin C levels, and all patients’ renal function and survival status were followed until March 2023. Cox-proportional hazard models were conducted to examine the association of cystatin C with incident CKD and all-cause mortality. A total of 146 patients were analyzed. After a median follow-up period of 10.7 years, patients with a higher cystatin C (≥ median vs. < median) were independently associated with a higher risk of incident CKD and all-cause mortality (adjusted hazard ratio [HR] 2.96, 95% CI 1.09 to 8.09, p = 0.034). The findings were consistent when cystatin C was analyzed as a continuous variable. The association was mainly observed in patients with prediabetes (adjusted HR 5.75, 95% CI 1.34 to 24.69, p = 0.019). In summary, a higher cystatin C was independently associated with risk of incident CKD and all-cause mortality in non-diabetes patients with an eGFR ≥ 60 mL/min/1.73 m2.